MAP2K7 and prostate cancer: For instance, in prostate cancer, DDR1 activates Pyk2 and MKK7 (Mitogen-activated protein kinase kinase 7), resulting in increased expression of the mesenchymal markers vimentin and N-cadherin and decreased expression of the epithelial marker E-cadherin [101].